On March 17, 2026, in United States ex rel. Adventist Health System of West v. AbbVie Inc., the United States Court of Appeals for the Ninth Circuit ruled that a 340B covered entity could pursue a False Claims Act qui tam case against drug companies that charged covered entities more than the 340B ceiling price . . .
Read More from Ninth Circuit 340B Decision Opens Up Whole New World Of Potential Qui Tam Cases
On January 22, 2026, the Department of Justice announced that it had reached a $1,823,100 settlement with Akris, Inc. (“Akris”), the United States subsidiary of Swiss fashion house Akris AG, to resolve allegations from Gregg Shapiro’s whistleblower client that Akris improperly obtained a $1,118,000 second draw Paycheck Protection Program loan. Gregg filed the whistleblower’s False . . .
On December 16, 2025, the U.S. Department of Justice announced that it had reached a $15 million settlement with Dana-Farber Cancer Institute to resolve False Claims Act allegations that Dana-Farber researchers relied on inaccurate biological images to win NIH grants. Eugenie Reich and her co-counsel Gregg Shapiro filed a False Claims Act qui tam complaint . . .
On December 12, 2025, the Department of Justice announced that it had reached a $2,092,371.92 settlement with KOKUSAI DENKI Electric America, Inc., formerly known as Hitachi Kokusai Electric Comark, LLC (“Hitachi Comark”), to resolve allegations from Gregg Shapiro’s whistleblower client that Hitachi Comark fraudulently obtained a $1,342,232 second draw Paycheck Protection Program loan. Gregg filed . . .
In an important development in the emerging body of caselaw on the application of the “but-for” causation standard to False Claims Act cases predicated on alleged violations of the anti-kickback statute, the court in United States ex rel. Witkin v. Medtronic, Inc., No. 1:11-cv-10790-IT (Nov. 14, 2025, D. Mass.), has once again denied Medtronic’s motion . . .
The Office of the Massachusetts Attorney General (“AGO”) has long been one of the nation’s leaders in pursuing False Claims Act cases at the state level. The AGO’s Medicaid Fraud Division and False Claims Division both have relatively new leaders – Kevin Lownds and Colleen Nevin, respectively – and their recent statements suggest that the . . .
Read More from Potential Whistleblower Opportunities Under The Massachusetts False Claims Act
On June 23, 2025, the Court of Appeals for the Ninth Circuit issued a decision holding that qui tam relators may pursue False Claims Act cases alleging customs fraud in United States District Courts even though the Court of International Trade (“CIT”) also affords the government a forum for recovering unpaid customs duties. See United . . .
Read More from Ninth Circuit Removes Cloud Over Qui Tam Cases Alleging Customs Fraud
On May 1, 2025, the Department of Justice filed a complaint in intervention in a qui tam case that Gregg Shapiro filed in 2021 on behalf of a whistleblower client against several of the nation’s largest Medicare Advantage insurance carriers and brokers. A copy of the government’s complaint is here, and a copy of the . . .
In a statement of interest (“SOI”) that it filed today in United States ex rel. Witkin v. Medtronic, Inc., No. 11-cv-10790-IT (D. Mass.), the United States reiterated its view that it need not prove but-for causation in a False Claims Act (“FCA”) case predicated on a false certification of compliance with the anti-kickback statute (“AKS”), . . .
In a recent decision, Omni Healthcare, Inc. v. MD Spine Solutions LLC (D. Mass. Jan. 6, 2025), the court held that the relator needed to show but-for causation in a False Claims Act case predicated on alleged violations of the anti-kickback statute. The anti-kickback statute provides that “a claim that includes items or services resulting . . .